Background <p>Transthyretin (TTR) amyloidosis is a progressive, life-threatening disorder caused by extracellular deposition of amyloid fibrils derived from the plasma protein TTR. Inherited forms are associated with destabilizing TTR mutations; however, recent findings indicate that amyloid formation in vivo may be promoted by disulfide bond formation between TTR subunits, suggesting oxidative stress as a potential contributor to protein misfolding and disease progression. Glutathione (GSH) is a central component of the antioxidant defense system, and disruption of GSH homeostasis can lead to the accumulation of pyroglutamate (PGA), which is detectable in plasma. Moreover, oxidative stress is frequently linked to inflammation, which may be reflected by increased indoleamine 2,3-dioxygenase 1 (<i>IDO1</i>) activity, observed as an elevated plasma kynurenine/tryptophan ratio.</p> Methods <p>Plasma levels of PGA, kynurenine, and tryptophan were quantified by liquid chromatography-mass spectrometry in cohorts comprising healthy TTR wild-type controls, asymptomatic carriers of the TTR-V30M mutation, and symptomatic patients with TTR-V30M amyloidosis.</p> Results <p>Symptomatic individuals had significantly elevated plasma PGA levels compared with both asymptomatic carriers and age-matched healthy controls, consistent with impaired GSH homeostasis. In parallel, the kynurenine/tryptophan ratio was increased in symptomatic TTR-V30M carriers, supporting inflammatory activation in manifest disease.</p> Conclusions <p>These findings identify disrupted GSH homeostasis and inflammatory activation as metabolic features associated with symptomatic TTR-V30M amyloidosis in vivo, supporting a link between redox imbalance and disease manifestation. Strategies aimed at restoring antioxidant homeostasis and limiting inflammatory oxidative stress may therefore warrant further investigation as approaches to delay onset or slow disease progression.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Disrupted glutathione homeostasis in the pathogenesis of TTR-V30M amyloidosis

  • Anushree Bachhar,
  • Gabriella Johannson,
  • Melisnur Sahin,
  • Sanduni Jayaweera,
  • Malin Olsson,
  • Intissar Anan,
  • Anders Olofsson

摘要

Background

Transthyretin (TTR) amyloidosis is a progressive, life-threatening disorder caused by extracellular deposition of amyloid fibrils derived from the plasma protein TTR. Inherited forms are associated with destabilizing TTR mutations; however, recent findings indicate that amyloid formation in vivo may be promoted by disulfide bond formation between TTR subunits, suggesting oxidative stress as a potential contributor to protein misfolding and disease progression. Glutathione (GSH) is a central component of the antioxidant defense system, and disruption of GSH homeostasis can lead to the accumulation of pyroglutamate (PGA), which is detectable in plasma. Moreover, oxidative stress is frequently linked to inflammation, which may be reflected by increased indoleamine 2,3-dioxygenase 1 (IDO1) activity, observed as an elevated plasma kynurenine/tryptophan ratio.

Methods

Plasma levels of PGA, kynurenine, and tryptophan were quantified by liquid chromatography-mass spectrometry in cohorts comprising healthy TTR wild-type controls, asymptomatic carriers of the TTR-V30M mutation, and symptomatic patients with TTR-V30M amyloidosis.

Results

Symptomatic individuals had significantly elevated plasma PGA levels compared with both asymptomatic carriers and age-matched healthy controls, consistent with impaired GSH homeostasis. In parallel, the kynurenine/tryptophan ratio was increased in symptomatic TTR-V30M carriers, supporting inflammatory activation in manifest disease.

Conclusions

These findings identify disrupted GSH homeostasis and inflammatory activation as metabolic features associated with symptomatic TTR-V30M amyloidosis in vivo, supporting a link between redox imbalance and disease manifestation. Strategies aimed at restoring antioxidant homeostasis and limiting inflammatory oxidative stress may therefore warrant further investigation as approaches to delay onset or slow disease progression.